# Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial

- Link: https://www.thailand-business-news.com/pr-news/bambusa-therapeutics-presents-positive-preliminary-phase-1-bbt002-data-at-american-thoracic-society-2026-ats-2026-international-conference-and-announces-first-patient-dosed-in-phase-1b-2a-crswnp-tri
- Published: 2026-05-18T20:15:00+07:00
- Author: PR Newswire

|   |

_– BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically
and commercially validated targets, IL-4Rα and IL-5 – _

_– Preliminary Phase 1 data demonstrated rapid, deep, and sustained effects on key
biomarkers for at least 8 weeks following a single dose, including pSTAT6 inhibition,
TARC reduction, and eosinophil depletion –_

_– BBT002 exhibited ~29.4-day half-life, supporting the potential for extended dosing
intervals – _

_– Topline data from ongoing Phase 1b/2a trials evaluating BBT002 in patients with
COPD and CRSwNP anticipated by year-end 2026 and first half of 2027, respectively–_

BOSTON, May 18, 2026 /PRNewswire/ — Bambusa Therapeutics, Inc. (Bambusa Therapeutics),
a clinical-stage biotechnology company advancing next-generation, long-acting bispecific
antibodies for immunology and inflammation, today announced the presentation of 
preliminary data from the single ascending dose (SAD) cohorts of the Phase 1 trial
evaluating BBT002 in healthy volunteers at the American Thoracic Society 2026 (ATS
2026) International Conference, taking place from May 17-20, 2026 in Orlando, Florida.

The Company also announced dosing of the first patient in the Phase 1b/2a trial 
evaluating BBT002 in patients with chronic rhinosinusitis with nasal polyps (CRSwNP),
expanding the ongoing clinical development of BBT002 across Type 2 inflammatory 
respiratory diseases, beyond chronic obstructive pulmonary disease (COPD).

"We are excited to present the first clinical data from BBT002 in an oral presentation
at ATS 2026. These data support the potential for BBT002 to deliver rapid and durable
biologic activity providing the opportunity for more complete clinical outcomes 
compared to currently approved medicines," said Thang Ho, Ph.D., Chief Development
Officer at Bambusa Therapeutics. "The Phase 1 SAD data demonstrate BBT002’s potential
to serve as a platform-in-a-molecule designed for respiratory and other Type 2 inflammatory
diseases in which eosinophils play an important pathogenic role."

The ATS 2026 oral presentation, titled _"Safety, Tolerability, Pharmacokinetics,
and Pharmacodynamics of BBT002, a Novel Bispecific IL-4Rα/IL-5 Antibody: Results
from the Single Ascending Dose Healthy Volunteers Portion of a Phase 1 Study"_ highlights
the following data:

Percent Change in Eosinophil (EOS) Levels: EOS is a clinically established biomarker
of Type 2 airway inflammation and IL-5 pathway activity, with elevated levels associated
with disease severity and exacerbation risk across multiple respiratory diseases.

 ◦ BBT002 demonstrated rapid, robust, and sustained depletion of EOS for more than
   8 weeks following a single dose compared to baseline.

Percent Change in Thymus and Activation-Regulated Chemokine (TARC): TARC is a key
Type 2 inflammatory chemokine that is associated with Th2-driven immune responses
and is strongly correlated with disease activity across multiple respiratory inflammatory
diseases.

 ◦ BBT002 demonstrated dose-dependent, rapid, deep, and sustained reduction in TARC
   for at least 8 weeks following a single dose compared to baseline.

Percent Change in Phosphorylated STAT6 (pSTAT6): pSTAT6 is a key downstream mediator
of Type 2 inflammation in respiratory inflammation disease when assessing IL-4R_α
_pathway activity.

 ◦ BBT002 achieved rapid, complete, and sustained inhibition of pSTAT6 for at least
   8 weeks following a single dose compared to baseline.

Pharmacokinetics (PK): BBT002 exhibited prolonged PK with a half-life of approximately
29.4 days at or above target exposure following a single dose, supporting the potential
for extended dosing intervals.

Safety and Tolerability: BBT002 was observed to be well-tolerated across all doses
evaluated in the SAD cohorts throughout the trial.

Immunogenicity: The incidence of anti-drug antibodies (ADA) was low, with no apparent
impact on safety or PK.

"We believe the clinical progress of BBT002 further validates the breadth and versatility
of Bambusa’s bispecific antibody platform and our strategy of developing differentiated,
long-acting therapies for significant immunology and inflammatory disease markets,"
said Shanshan Xu, M.D., Ph.D., Founder & Chief Executive Officer of Bambusa Therapeutics."
With encouraging early Phase 1 PK, PD, and safety data, the advancement of BBT002
into patients with CRSwNP, and multiple upcoming clinical milestones including topline
data from our ongoing COPD trial, we continue to demonstrate our ability to rapidly
advance innovative bispecific antibodies that address complementary, clinically 
and commercially validated pathways within a single molecule. Together, BBT001 and
BBT002 highlight our pipeline-in-a-program approach, which we believe has the potential
to drive more complete clinical outcomes, enhanced dosing convenience enabled through
prolonged half-life, and meaningful differentiation across multiple large inflammatory
diseases."

The Company also expects to present data from the MAD cohorts of the BBT002 Phase
1 trial in healthy volunteers at European Academy of Allergy & Clinical Immunology(
EAACI) Annual Congress 2026, taking place June 12-15, 2026, in Istanbul, Turkey.
In parallel to the Phase 1 SAD and MAD trial in healthy volunteers, BBT002 is being
evaluated in ongoing Phase 1b/2a trials in patients with COPD and CRSwNP, with topline
results anticipated by year-end 2026 and the first half of 2027, respectively.

The BBT002 Phase 1 trial presentation from ATS 2026 is available in the "Publications"
section on Bambusa’s website, [www.bambusatx.com](https://www.bambusatx.com/).

**About the Phase 1 SAD/MAD trial of BBT002**

Bambusa Therapeutics’ single- and multiple-ascending-dose Phase 1 clinical trial
in healthy volunteers is a randomized, blinded, placebo-controlled trial designed
to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamic
profile of BBT002.

**About BBT002**

Bambusa Therapeutics’ second clinical program, BBT002, is a first-in-class, multi-
targeting, half-life extended bispecific antibody engineered to inhibit both IL-
4Rα and IL-5 signaling. Designed as a platform-in-a-molecule, BBT002 simultaneously
targets the IL-4/IL-13 pathway through IL-4Rα and the IL-5/eosinophil axis within
a single therapy. The Company believes this differentiated approach has the potential
to address multiple respiratory and other Type 2 inflammatory diseases, improve 
clinical outcomes, and provide greater dosing convenience through extended maintenance
dosing intervals. BBT002 has demonstrated a favorable safety profile and strong 
pharmacokinetics in healthy volunteers, supporting its advancement into multiple
clinical trials in patients with COPD and CRSwNP.

**About Bambusa Therapeutics**

Bambusa Therapeutics is a clinical-stage biotechnology company developing a portfolio
of next-generation, multi-targeting medicines designed to transform patient care
across chronic immunology and inflammation (I&I) diseases. The Company’s bispecific
antibody platform combines advanced protein engineering with half-life extension
technology and high-concentration subcutaneous delivery to improve durability, convenience,
and clinical differentiation. Bambusa’s vision is to deliver transformative medicines
for patients across every stage of life and help define the next era of I&I therapies.

 ◦ BBT001 is a first-in-class, half-life-extended bispecific antibody targeting 
   IL-4Rα and IL-31 with best-in-disease potential. It is currently in Phase 1b/
   2a proof-of-concept development for atopic dermatitis (AD) and chronic spontaneous
   urticaria (CSU).
 ◦ BBT002 is a first-in-class, half-life-extended bispecific antibody targeting 
   IL-4Rα and IL-5 with platform-in-a-molecule potential. It is currently in Phase
   1b/2a proof-of-concept development for Type 2 inflammatory disorders, including
   COPD and CRSwNP.
 ◦ BBT003 and BBT004 are preclinical programs focused on gastroenterology and rheumatology,
   respectively.

For more information, please visit [www.bambusatx.com](https://bambusatx.com/). 
Follow Bambusa on [LinkedIn](https://www.linkedin.com/company/bambusatherapeutics/).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial ](http://www.prnasia.com/story/archive/4961389_CN61389_0?rand=184833)
